# JNJ Stock Analysis: Rising Analyst Confidence and Strategic Growth in Healthcare Giant
Discover why Johnson & Johnson (JNJ) is gaining momentum as analysts shift from "hold" to "moderate buy" recommendations. This episode explores JNJ's impressive quarterly performance with EPS reaching $2.77 and revenue growing nearly 6% year-over-year. Learn about the company's strategic investments in robotic-assisted surgery technology and how this healthcare leader maintains its status with 62 consecutive years of dividend increases and a current yield near 3%.
We analyze JNJ's remarkable 22% growth since January and its $426+ billion market cap, while also addressing challenges including talcum powder litigation and drug pricing pressures. Understand why major brokerages like Wolfe Research are raising price targets above consensus and what JNJ's upgraded financial guidance for 2025 signals about its future prospects. Perfect for investors seeking both stability and growth in today's dynamic healthcare sector.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
